The researchers worked with 20 people between the ages of 45 and 82 who were diagnosed with chronic lymphocytic leukaemia but had not yet begun treatment. Participants were asked to do a 30 minute bout of moderate-to-vigorous intensity cycling. Blood samples were taken before and immediately after the exercise bout, and then a third sample was taken an hour later.
In the blood samples, under ‘ex vivo’ conditions, the researchers measured the number of natural killer cells present at each of the sample points and tested their ability to kill cancer cells with and without Rituximab present.
They found the number of natural killer cells increased by 254% after exercise and that in the blood samples taken after exercise, there were 67% more cancer cells compared to blood before exercise.
Next, the team isolated natural killer cells and put them in close contact with cancer cells for 2 hours ‘ex vivo’ with and without the antibody therapy Rituximab. When Rituximab was also present in the blood sample, natural killer cells were just over twice as effective in killing the cancer cells in the samples collected immediately after exercise compared to before.
Dr John Campbell, senior author of the study at the University of Bath said: “Cancer cells often try to ‘hide’ in the body but it seems that exercise works to move them out into the bloodstream, where they are vulnerable to the antibody therapy and the killing capabilities of natural killer cells”.
The results of the study could also have potential for patients who have finished their treatment for leukaemia and are in a monitoring phase in case cancer cells re-appear.
Dr Harrison Collier-Bain, first author of the study at the University Bath said: “Monitoring patients after treatment is complicated because if cancer cells remain or reappear, they are sometimes too low to detect, but a bout of exercise followed by a blood sample immediately afterwards could help to ‘find’ them if they are ‘hiding’ in the body”.
While these results are promising, larger-scale trials would needed in a cohort of patients undergoing Rituximab treatment before treatment recommendations could be made.
Caroline Geraghty, Senior Specialist Information Nurse at Cancer Research UK, said: “This study adds to a growing body of evidence showing that exercise can be helpful before, during and after cancer treatment. We know that being physically active before and after treatment can help cancer patients cope better with treatment, aid recovery and improve mental wellbeing. It is interesting to see that exercise could also improve the efficacy of treatment for some types of blood cancer, although more research in a larger group of patients is needed.
“Everyone has different needs and abilities, so it’s important that you discuss with your doctor what forms of exercise would work best for you. We encourage all cancer patients to seek their doctor’s advice before starting a programme of exercise before or after treatment, to make sure that the activities suggested are appropriate for them.”
